The sustainability and maintenance of insulin secretion following OSA® exposure may provide therapeutic benefits in long-term glycemic control and thus reduce dosing frequency, although careful dosage would be needed to avoid potential hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.